Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib + Luspatercept in Transfusion Dependent Myelofibrosis
NCT06517875Phase 2Recruiting
- Sponsor
- GSK
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of mivavotinib, luspatercept in myelofibrosis (MF), sponsored by GSK. Started Feb 2025; status: recruiting.
02
Drugs
mivavotinibluspatercept
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06517875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517875.